A comprehensive site-specific analysis of patient-specific quality assurance based on dose volume histogram of RapidArc treatment delivery
Abstract
Background: The current study aims to evaluate the use of dose-volume histogram (DVH) metrics as part of a comprehensive pre-treatment quality assurance (PSQA) protocol for RapidArc treatment delivery.
Materials and methods: A total of ninety patients were included in this study, with the patient population divided into four groups: Brain (n = 15), Head and Neck (H & N) (n = 30), Thorax (n = 15), and Pelvis (n = 30) RapidArc plans. The delivered dose was assessed using the Octavius 4D 1500 detector array and the Verisoft DVH application, focusing on DVH-related errors pertaining to targets and organ-at-risk (OARs). Additionally, three-dimensional local and global gamma passing rates were analyzed in the axial, coronal, and sagittal planes using various gamma criteria, including 3 mm/3%, 3 mm/2%, 2 mm/3%, and 2 mm/2%.
Results: All treatment plans met the action level requirement, achieving a gamma acceptance rate exceeding 95% with a 3%/3 mm criterion. Among the anatomical planes, the transverse plane consistently exhibited the highest passing rates for various global gamma criteria across all treatment sites. Local gamma analysis revealed that the coronal plane had the highest passing rates for thorax and pelvis sites compared to other planes. DVH analysis indicated that doses to target volumes remained within specified tolerances for all cases. The most significant OAR dose discrepancies were observed in the H&N region.
Conclusion: Integrating DVH metrics into the RapidArc PSQA protocol can yield clinically significant results closely aligned with the gamma index. It was observed that a single action-level approach cannot be universally applied to DVH metrics across different anatomical sites.
Keywords: gamma indexdose volume histogramrapidArcpatient specific quality assuranceOctavius 4D
References
- Li J, Zhang X, Li J, et al. Impact of delivery characteristics on dose delivery accuracy of volumetric modulated arc therapy for different treatment sites. J Radiat Res. 2019; 60(5): 603–611.
- Chan GH, Chin LCL, Abdellatif A, et al. Survey of patient-specific quality assurance practice for IMRT and VMAT. J Appl Clin Med Phys. 2021; 22(7): 155–164.
- Bakhtiari M, Kumaraswamy L, Bailey DW, et al. Using an EPID for patient-specific VMAT quality assurance. Med Phys. 2011; 38(3): 1366–1373.
- Dogan N, Mijnheer BJ, Padgett K, et al. AAPM Task Group Report 307: Use of EPIDs for Patient-Specific IMRT and VMAT QA. Med Phys. 2023; 50(8): e865–e903.
- Manna S. Evaluation of Patient-Specific Quality Assurance for RapidArc Treatment Delivery Using Dose Volume Histogram. J Polymer Compos. 2023.
- Low DA, Harms WB, Mutic S, et al. A technique for the quantitative evaluation of dose distributions. Med Phys. 1998; 25(5): 656–661.
- Low DA, Moran JM, Dempsey JF, et al. Dosimetry tools and techniques for IMRT. Med Phys. 2011; 38(3): 1313–1338.
- Ezzell GA, Burmeister JW, Dogan N, et al. IMRT commissioning: multiple institution planning and dosimetry comparisons, a report from AAPM Task Group 119. Med Phys. 2009; 36(11): 5359–5373.
- Song JHo, Shin HJ, Kay CS, et al. Dosimetric verification by using the ArcCHECK system and 3DVH software for various target sizes. PLoS One. 2015; 10(3): e0119937.
- Vikraman S, Manigandan D, Karrthick KP, et al. Quantitative evaluation of 3D dosimetry for stereotactic volumetric-modulated arc delivery using COMPASS. J Appl Clin Med Phys. 2014; 16(1): 5128.
- Stelljes TS, Harmeyer A, Reuter J, et al. Dosimetric characteristics of the novel 2D ionization chamber array OCTAVIUS Detector 1500. Med Phys. 2015; 42(4): 1528–1537.
- Stasi M, Bresciani S, Miranti A, et al. Pretreatment patient-specific IMRT quality assurance: a correlation study between gamma index and patient clinical dose volume histogram. Med Phys. 2012; 39(12): 7626–7634.
- Thomas SJ. Relative electron density calibration of CT scanners for radiotherapy treatment planning. Br J Radiol. 1999; 72(860): 781–786.
- Urso P, Lorusso R, Marzoli L, et al. Practical application of Octavius -4D: Characteristics and criticalities for IMRT and VMAT verification. J Appl Clin Med Phys. 2018; 19(5): 517–524.
- Lehmann J, Hussein M, Barry MA, et al. SEAFARER — A new concept for validating radiotherapy patient specific QA for clinical trials and clinical practice. Radiother Oncol. 2022; 171: 121–128.
- Das S, Kharade V, Pandey VP, et al. Gamma Index Analysis as a Patient-Specific Quality Assurance Tool for High-Precision Radiotherapy: A Clinical Perspective of Single Institute Experience. Cureus. 2022; 14(10): e30885.
- Miften M, Olch A, Mihailidis D, et al. Tolerance limits and methodologies for IMRT measurement-based verification QA: Recommendations of AAPM Task Group No. 218. Med Phys. 2018; 45(4): e53–e83.
- Lu W, Li Y, Huang W, et al. Optimizing the Region for Evaluation of Global Gamma Analysis for Nasopharyngeal Cancer (NPC) Pretreatment IMRT QA by COMPASS: A Retrospective Study. Front Oncol. 2022; 12: 859415.
- Du W, Cho SH, Zhang X, et al. Quantification of beam complexity in intensity-modulated radiation therapy treatment plans. Med Phys. 2014; 41(2): 021716.
- Low C, Toye W, Phung P, et al. Patient-Specific Quality Assurance Protocol for Volumetric Modulated Arc Therapy using Dose Volume Histogram. J Med Phys. 2018; 43(2): 112–118.
- Park JM, Kim JI, Park SY, et al. Reliability of the gamma index analysis as a verification method of volumetric modulated arc therapy plans. Radiat Oncol. 2018; 13(1): 175.
- Rajasekaran D, Jeevanandam P, Sukumar P, et al. A study on the correlation between plan complexity and gamma index analysis in patient specific quality assurance of volumetric modulated arc therapy. Rep Pract Oncol Radiother. 2015; 20(1): 57–65.
- Gong C, Zhu K, Lin C, et al. Efficient dose-volume histogram-based pretreatment patient-specific quality assurance methodology with combined deep learning and machine learning models for volumetric modulated arc radiotherapy. Med Phys. 2022; 49(12): 7779–7790.
- Chen L, Luo H, Li S, et al. Pretreatment patient-specific quality assurance prediction based on 1D complexity metrics and 3D planning dose: classification, gamma passing rates, and DVH metrics. Radiat Oncol. 2023; 18(1): 192.
- Nelms B, Stambaugh C, Hunt D, et al. Methods, software and datasets to verify DVH calculations against analytical values: Twenty years late(r). Med Phys. 2015; 42(8): 4435–4448.
- Cozzolino M, Oliviero C, Califano G, et al. Clinically relevant quality assurance (QA) for prostate RapidArc plans: gamma maps and DVH-based evaluation. Phys Med. 2014; 30(4): 462–472.
- Visser R, Wauben DJL, de Groot M, et al. Evaluation of DVH-based treatment plan verification in addition to gamma passing rates for head and neck IMRT. Radiother Oncol. 2014; 112(3): 389–395.
- Yi X, Lu WL, Dang J, et al. A comprehensive and clinical-oriented evaluation criteria based on DVH information and gamma passing rates analysis for IMRT plan 3D verification. J Appl Clin Med Phys. 2020; 21(8): 47–55.
- Coleman L, Skourou C. Sensitivity of volumetric modulated arc therapy patient specific QA results to multileaf collimator errors and correlation to dose volume histogram based metrics. Med Phys. 2013; 40(11): 111715.
- Racka I, Majewska K, Winiecki J. Three-dimensional conformal radiotherapy (3D-CRT) vs. volumetric modulated arc therapy (VMAT) in deep inspiration breath-hold (DIBH) technique in left-sided breast cancer patients-comparative analysis of dose distribution and estimation of projected secondary cancer risk. Strahlenther Onkol. 2023; 199(1): 90–101.
- Tang Du, Yang Z, Dai X, et al. Evaluation of Delta Anatomy in 3D Patient-Specific IMRT Quality Assurance. Technol Cancer Res Treat. 2020; 19: 1533033820945816.
- Zhang H, Lu W, Cui H, et al. Assessment of Statistical Process Control Based DVH Action Levels for Systematic Multi-Leaf Collimator Errors in Cervical Cancer RapidArc Plans. Front Oncol. 2022; 12: 862635.
- Mohamed Yoosuf AB, AlShehri S, Alhadab A, et al. DVH analysis using a transmission detector and model-based dose verification system as a comprehensive pretreatment QA tool for VMAT plans: Clinical experience and results. J Appl Clin Med Phys. 2019; 20(11): 80–87.
- Guo Y, Hu J, Li Y, et al. Correlation between patient-specific quality assurance in volumetric modulated arc therapy and 2D dose image features. Sci Rep. 2023; 13(1): 4051.
- RP S. Gamma Evaluation with Octavius 4D Phantom for PreTreatment of Modern Radiotherapy Treatment Techniques. Int J Nucl Med Radioact Subst. 2019; 2(2).
- Sadagopan R, Bencomo JA, Martin RL, et al. Characterization and clinical evaluation of a novel IMRT quality assurance system. J Appl Clin Med Phys. 2009; 10(2): 104–119.